All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
MagnetisMM-3: Long-term survival after elranatamab monotherapy in patients with RRMM
|
Data from the phase II MagnetisMM-3 trial (NCT04649359) demonstrates deep and durable responses to elranatamab monotherapy in patients with relapsed/refractory multiple myeloma (RRMM). In the BCMA-naive arm (Cohort A; n = 123), the primary endpoint of overall response rate (ORR) was 61% at a median follow-up of 17.6 months. Updated results in BCMA-naive patients after 2 years of follow-up were presented by Mohamad Mohty at the European Hematology Association (EHA) 2024 Hybrid Congress.1
|
| Key learnings: |
| In the phase II MagnetisMM-3 trial, the ORR remained at 61% after >2 years of follow-up, with 37.4% of patients achieving ≥CR. |
| The rate of MRD negativity was 90.3% in evaluable patients achieving ≥CR (n = 31). |
| The median PFS was 17.2 months, and the median OS was 24.6 months. |
| The median duration of response was not reached; the probability of maintaining at response at 2 years was 66.9% for all responders and 87.9% in patients achieving ≥CR. |
| No new safety signals were observed. A small number of secondary primary malignancies (SPMs) (<5%) and no hematologic SPMs were reported. |
| These findings demonstrate the durable long-term efficacy of elranatamab in heavily pretreated patients with BCMA-naive RRMM and supports the continued evaluation of the efficacy and safety of elranatamab across patient populations with MM. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content